Category Archives: Healthcare Technology

Path03Gen Is Taking a Step In the Right Direction to Reduce Healthcare-Associated Infections (HAI’s)

Amazing research and developments are taking place all across the globe.

In St. Petersburg, Florida there is an organization dedicated in fighting  harmful pathogens and the St. Pete Catalyst’s Journalist Margie Manning had the following to report on the “Green Earth Medical Solutions” technology company:

Green Earth Medical Solutions developed technology that kills germs on the bottom of shoes, which often are overlooked as a source for bacteria, virus and other disease-causing microorganisms.

The company’s PathO3Gen sanitizing stations combine UVC, a type of ultraviolet light, and ozone, to sanitize shoes. Anyone entering a healthcare facility or a critical care area steps on the station and waits for about six seconds. When they step off, 99.9 percent of the deadly pathogens have been eliminated, said chief operating officer Scott Beal.

Healthcare acquired infections, or HAIs, cause about 100,000 deaths every year, according to the Centers for Disease Control and Prevention. There’s been a lot of attention paid to infection control in healthcare, most of it focused on hand washing and cleaning high-touch surfaces. A 2017 clinical study showed 77 percent of the soles of shoes walking into a hospital contained superbugs such as MRSA and C. difficile, or a combination of the two.

“Initially, clinicians said ‘we don’t operate on the floors, those are not areas of concern,’” Beal said. “But the infection control community and stakeholders have been coming out with more and more published credible studies that say what is tracked in on the floor is getting airborne and aerosolized, and makes it to high-touch areas, which then cause HAIs.”

Reducing pathogens tracked in by shoes also increases the efficacy of other sanitizing methods, because the building is not being overrun by germs, Beal said.

Hospitals have financial reasons to reduce hospital-acquired infections. Beginning in 2015, federal reimbursements to hospitals were directly affected by their HAI rates.

AdventHealth Connerton, an acute-care specialty hospital in Pasco County, is testing the technology.

“The sanitizing stations allow us to establish new protocols that proactively prevent infections to ensure the best possible outcomes for patients while they’re in our care,” Debi Martoccio, chief operating officer at AdventHealth Connerton, said in a statement.

With any new technology, gaining traction and changing minds are tough to do, Beal said.

“It’s important to have someone the size and scope and reputation of AdventHealth that sees the benefit of what we are trying to accomplish,” he said.

There also are foot sanitizing stations at Cypress Creek Assisted Living in Sun City Center.

There are competitors that use UVC to disinfect shoes, Beal said. None of those companies combine UVC with ozone, a combination initially created by Asher Gil, an Israeli aeronautical engineer. Gil tested his combination of UVC and ozone at University of South Florida. Gil was bought out about three years ago by his partners, who further developed the technology and ran clinical tests. The product went to market in the fourth quarter of 2018.

Those initial owners and one outside investor have provided the capital for Green Earth Medical, now in its second round of fundraising, Beal said.

The company is headquartered in downtown St. Petersburg. It has four full-time employees, and contracts with distributors to market the sanitizing stations. There are about 25 to 30 representatives in the field marketing the product, and the company is in the early stages of talks with more healthcare facilities, as well as clean rooms and labs, Beal said.

The sanitizing stations are the only product right now, but other products are in the process of being patented, he said. He expects to ramp up development on those once the company gains traction.

“We are out trying to market, educate, change perceptions and shift the paradigms that exist around infection controls,” Beal said. “Our goal is to reduce bioburden in every facility that has an immune-compromised population.”

RESOURCE;  https://stpetecatalyst.com/st-pete-tech-company-steps-into-hospital-safety/

.

ABC ACTION NEWS INTERVIEW WITH DEBI MORTOCCIO, COO – ADVENTHEALTH  CONNERTON

 

 

Multidisciplinary Program Duke University Medical Center Included UVC Disinfection Technology To Reduce Hospital-Acquired Infections Including CDI

IN THE NEWS………………..

A new manuscript has been accepted by the Journal of the American College of Surgeons which examines C. diff in adult surgical patients. The paper, “Multidisciplinary Approach and Clostridium difficile Infection in Adult Surgical Patients,” discusses the multidisciplinary program that Duke University Medical Center implemented to reduce its C. diff rate.

In 2017, Duke University Medical Center was identified as a “High Outlier” for postoperative C. diff infections in the American College of Surgeons NSQIP semi-annual report with .4 percent cases per year with an increased risk in morbidity and mortality. To address the issue,

“The Department of Surgery initiated a CDI Task Force with representation from Surgery, Infectious Disease, Pharmacy and Performance Services to analyze available data, identify opportunities for improvement and implement strategies to reduce CDI,” the manuscript states.

Strategies to reduce CDI included antimicrobial stewardship optimization, increased use of Tru-D SmartUVC for terminal cleaning of CDI patient rooms, increased hand hygiene and PPE signage as well as monitoring in high-risk CDI areas, improved diagnostic stewardship by an electronic best practice advisory to reduce inappropriate CDI testing, education through surgical grand rounds and routine data feedback via NSQIP and NHSN CDI reports.

Using these strategies, observed rate of C. diff decreased from 1.27 percent in 2016 to 0.91 percent in 2017, a 28 percent decrease.

“Reducing hospital-acquired infections, especially C. diff, takes a multidisciplinary approach and a commitment to numerous infection prevention protocols,” Alice Brewer, MPH, CIC, Director of Clinical Affairs for Tru-D SmartUVC, said.

As one of the strategies, “We reviewed the terminal cleaning policies for rooms occupied by patients with known CDI once they were discharged from the hospital,” the authors stated. “Additionally, the success at eliminating C. difficile through the established terminal cleans was verified through an auditing process. However, the audit demonstrated that there was variability and ineffective cleaning practices within the hospital system. These deficiencies were largely due to lack of Environmental Services staff and staff trained in Tru-D technology.”

The conclusion provided a basis for requesting the hiring and training of additional Environmental Services staff and “expanded training for terminal cleans was used for the Tru-D technology system, a system which uses an ultraviolet light cleaning system to denature the spores of C. difficile. This provided more effective terminal cleaning.”

By training five additional Tru-D operators, the facility went from using Tru-D on 30 percent of C. diff rooms to 100 percent of C. diff rooms. “Appropriately trained Tru-D technicians increased in number following the initiative from two in 2017 to seven in 2019.

This increase in technicians allowed for an increase in terminal cleans by Tru-D Ultraviolet therapy from 30 percent in March 2017 to 100 percent in September 2018,” the manuscript states.

Validated by multiple studies including the only randomized clinical trial on UVC disinfection, Tru-D has been proven to be a chemical-free and environmentally-friendly way of providing thorough room disinfection. UVC is a type of energy that is invisible to the human eye. Its wavelengths are between 200 and 300 nanometers, making them germicidal – meaning they are capable of inactivating microorganisms, such as bacteria, viruses and protozoa.

“It has been proven that increased utilization of Tru-D and UVC disinfection technology correlates to a reduction in hospital-acquired infections, including C. diff,” Brewer said. “By training additional staff in the operation of Tru-D, Duke was able to achieve 100 percent utilization, which helped to contribute to the 28 percent reduction in C. diff infections.”

To Read Article In Its Entirety – Please Click On the Following Link To Be Redirected:

https://www.prnewswire.com/news-releases/duke-university-medical-center-reduces-postoperative-c-diff-rates-with-bundled-approach-300800682.html

Merck and Premier Applied Sciences Will Develop Software To Provide C.difficile Infection Education and Provide Surveillance

Merck & Co is working a major US hospital provider on a new software system that could help tackle the threat from healthcare-associated infections, the leading HAI:   C. diff.  infections.

 

 

 

The pharma company’s deal with Premier will see the partners develop and test the combination of a software-based platform and a coordinator to provide surveillance, consultation, support and education to patients with Clostridium difficile infection (C. diff).

Sam Bozzette, MD, chief scientist of Premier’s retrospective and interventional research division Premier Applied Sciences, said: “By increasing clinician and patient knowledge of this often prolonged, and sometimes deadly infection, and developing and testing a software-based application to help reduce the recurrence of C. diff. infection by improving follow-up and management, we believe there is a strong potential to make a real difference to address this critical public health problem.”

Sam Bozzette, MD, PhD, vice president and chief scientist of its retrospective and interventional research division, Premier Applied Sciences.  An internationally-recognized researcher and physician executive, Dr. Bozzette provides strategic clinical, analytical and operational direction to further grow the Premier Applied Sciences research business and improve the overall quality, safety and cost-effectiveness of care.  “Dr. Bozzette is a leader in medical and social sciences, and has more than 25 years of experience working with academic and non-profit healthcare providers to improve clinical decision-making practices, care delivery efficiency and effectiveness, and population health management,” said Leigh Anderson, chief information officer at Premier. “We are thrilled to have him on board to lead Premier’s data-driven research efforts to set new standards in care delivery through strategic partnerships with healthcare industry leaders across the U.S.”

Premier Applied Sciences, formerly known as Premier Research Services, combines data and analytics with objective clinical outcomes analyses, and partnerships with health systems, life sciences companies, academic institutions and professional societies to develop, teach, test and research care delivery practices and real-world interventions for healthcare improvement. It offers real-world research and analytics, retrospective research, healthcare education, clinical trial innovation and data licensing services.

Resources:  https://pharmaphorum.com/news/merck-co-software-c-diff-infections/

https://www.premierinc.com/dr-sam-bozzette-joins-premier-inc-lead-research-division/

The work expands Merck’s chronic disease work with Premier, which has seen them co-develop and test solutions that help promote wellness and prevention for specific groups of at-risk patients since 2016.

Raquel Tapia, associate VP, hospital/specialty marketing at Merck, said: “Combining the technical capabilities of Premier and the therapeutic area expertise of Merck has been instrumental in our ability to address these difficult healthcare challenges.

“By testing the solutions in real-world settings and learning from our growing knowledge base, we’re confident that our work together will help patients.”

The partners’ goal is to increase patient access to healthcare services, raise awareness of how to decrease patient risk of recurrence and help patients identify if they are having a recurrence.

The proposed C. diff software intervention will be tested within volunteer Premier member health systems. The firm current has an alliance of around 3,900 US hospitals and health systems and a further 150,000 or so healthcare providers and organizations.

C. diff infections cause serious and life-threatening diarrhea and have become one of the most common microbial cause of healthcare-associated infections in US hospitals. It’s thought that C. diff infections affect approximately half a million people and add $4.8 billion to US healthcare costs each year.

California Hemet Valley Medical Center Adds UV Technology to Enhance Patient Safety

Hemet Valley Medical Center has implemented innovative ultraviolet technology with the addition of the Clorox Healthcare® Optimum-UV® System. The system helps remove harmful bacteria and pathogens that can jeopardize health, providing patients, visitors and staff with an additional layer of safety and protection.

Researchers at Boston-based Massachusetts General Hospital, Ann Arbor-based University of Michigan and Cambridge-based Massachusetts Institute of Technology Are Developing Institution-Specific Models That Predict Patient’s Risk Of Acquiring C.diff. Infections

Researchers at Boston-based Massachusetts General Hospital, Ann Arbor-based University of Michigan and Cambridge-based Massachusetts Institute of Technology are developing hospital-specific machine learning models that predict patients’ risk of Clostridium difficile infections much sooner than current diagnostic methods allow, according to a study published in Infection Control & Epidemiology.

“Despite substantial efforts to prevent C. diff infection and to institute early treatment upon diagnosis, rates of infection continue to increase,” co-senior study author Erica Shenoy, MD, PhD, said in a press release. “We need better tools to identify the highest risk patients so that we can target both prevention and treatment interventions to reduce further transmission and improve patient outcomes.”

The study authors noted most previous approaches to C. diff  infection risk were limited in usefulness since they were not hospital-specific and were developed as “one-size-fits-all” models that only included a few risk factors.

Therefore, to predict a patient’s C. diff risk throughout the course of their hospital stay, the researchers took a “big data” approach that analyzed the entire EHR. This method allows for institution-specific models that could be tailored to different patient populations, different EHR systems and factors specific to each facility. 

“When data are simply pooled into a one-size-fits-all model, institutional differences in patient populations, hospital layouts, testing and treatment protocols, or even in the way staff interact with the EHR can lead to differences in the underlying data distributions and ultimately to poor performance of such a model,” said co-senior study author Jenna Wiens, PhD. “To mitigate these issues, we take a hospital-specific approach, training a model tailored to each institution.”

With this machine learning-based model, the researchers looked at de-identified data, which included individual patient demographics and medical history, details on admissions and daily hospitalization, and the likelihood of C. diff exposure. The data was gathered from the EHRs of roughly 257,000 patients admitted to either MGH or to Michigan Medicine over two-year and six-year periods, respectively.

The models proved to be highly successful at predicting patients who would ultimately be diagnosed with C. diff. In half of these infected patients, accurate predictions could have been made at least five days before collecting diagnostic samples, which would allow hospitals to focus on antimicrobial interventions on the highest-risk patients.

The study’s risk prediction score could guide early screening for C. diff if validated in subsequent studies. For patients who receive an earlier diagnosis, treatment initiation could curb illness severity, and patients with confirmed C. diff could be isolated to prevent transmission to other patients.

The algorithm code is freely available here for hospital leaders to review and adapt for their institutions. However, Dr. Shenoy notes facilities looking to apply similar algorithms to their own institutions must assemble the appropriate local subject-matter experts and validate the performance of the models in their institutions.

To read article in its entirety please click on the following link to be redirected:

https://www.beckershospitalreview.com/quality/how-machine-learning-models-are-rapidly-predicting-c-diff-infections.html

Xenex Disinfection Services’ LightStrike™ Robot With Pulsed Xenon Ultraviolet-C (UV-C) Light Technology Introduces Its LightStrike Disinfection Pod

The scientific evidence has clearly established that in the hospital environment, microorganisms such as Clostridium difficile (C.diff), Methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE) are responsible for the infections that kill nearly 300
people in the U.S. every day.

Xenex Disinfection Services’ LightStrike™ Robot with pulsed xenon ultraviolet-C (UV-C) light technology is a proven solution that quickly destroys deadly viruses, bacteria and spores before they pose a threat to patients and healthcare workers. LightStrike Robots help healthcare facilities reduce their HAI rates by destroying the microscopic germs that may be missed during the manual cleaning process. Xenex robots use pulsed xenon, a noble gas, to create Full Spectrum™, high intensity UV light that quickly destroys infectious germs in less than five minutes. Hospitals using Xenex devices have published clinical outcome studies in peer-reviewed journals showing 50-100 percent reductions in C.diff, MRSA and Surgical Site Infection rates when those hospitals used LightStrike Robots to disinfect rooms.

Ingenia MR-OR intraoperative MRI delivers high-quality images during neurosurgical procedures. It helps you gain up-to-date insight on surgical procedures & tumor resection & supports smooth, in-line patient transfer between the OR and Philips Ingenia MR


Now, for the first time, hospitals can utilize the power of

LightStrike Germ-Zapping Robots™ to quickly disinfect mobile equipment just as effectively as they disinfect rooms within their facility. Pathogens like C.diff, Acinetobacter baumannii, MRSA and Vancomycin-Resistant Enterococci (VRE) can travel throughout a healthcare facility on mobile equipment.

To address this gap in the infection control process, Xenex recently partnered with an industry leader in containment units, Mintie Technologies, Inc., to create the LightStrike Disinfection Pod.

Designed to quickly disinfect reusable mobile equipment such as isolettes, ventilators, pressure monitors, wheelchairs and workstations, the

LightStrike Disinfection Pod enables the power of the LightStrike Robot’s intense, germicidal light to be used anywhere in a facility.
The Pod is collapsible, mobile and can be positioned in a hospital hallway or other areas without disrupting or impeding daily workflow. Its proprietary design integrates reflective interior fabric ensuring 360 degrees of UV light coverage over difficult-to-clean equipment including anesthesia carts, ventilators, and mobile imaging machines.

To access and read the article in its entirety please click on the link below:

https://www.dotmed.com/news/story/37771

UV-C Disinfecting Takes Its Place At Thompson Hospital and the M.M. Ewing Continuing Care Center in New York State

 

UV Disinfecting

Accomplished by using  short-wave
ultraviolet-C (UV-C) light as a germicidal to destroy viruses, bacteria and other pathogens that can linger on surfaces and hide in shadows.

One piece of equipmnet can disinfect an average-sized patient room in about 8 minutes and is deployed after a room is sanitized with standard techniques and cleaning products.

In  Canandaigua, New York  a nearly 6 foot tall and wielding 20 vertical fluorescent bulbs, the R-D Rapid Disinfector robot is a formidable fighter in the war against germs.

This UV disinfecting robot is The R-D Rapid Disinfector — developed by a Rochester, New York  firm, Steriliz LLC, and is manufactured locally.

Thompson Hospital and the M.M. Ewing Continuing Care Center have begun using this automated disinfecting machine throughout the institutions to help reduce the risks of illness and infections for patients, residents, visitors and staff.

The Disinfector uses short-wave ultraviolet-C (UV-C) light as a germicidal to destroy viruses, bacteria and other pathogens that can linger on surfaces and hide in shadows. This machine can disinfect an average-sized patient room in about 8 minutes and is deployed after a room is sanitized with standard techniques. It is remotely controlled by an associate from Environmental Services.

The UV-C light fills the entire room, reaching and disinfecting areas that human hands might miss. No one is allowed inside the room when the lights are working. This no-touch cleaning system gets rid of some of the most dangerous and difficult-to-destroy bacteria, including Clostridium difficile (C. diff). Disinfectants work on the surface of non-living objects by destroying the cell wall of harmful microbes or interfering with their metabolism.

“This technology, added on to normal, regular, manual environmental cleaning, gives me a sense of ease that we are doing all we can to keep our environment clean and our patients safe,” said Thompson Health Director of Infection Prevention Michelle Vignari. “We are just now starting to see published literature supporting that the addition of UV-C technology in hospitals actually does correlate with a reduction of healthcare-acquired infections.”

This state-of-the-art robot monitors the entire disinfection process. Wireless sensors measure, record and report on UV-C light dosages delivered to specific areas in real time. The machine can be paused and repositioned to maximize efficiency, including targeting shadowed areas. The Disinfector shuts off automatically once the sensors indicate that enough UV-C light has been emitted to kill the germs.

“In a day of delivering high-reliability care, I felt very strongly that we needed a technology that we could measure and evaluate its performance,” Vignari said.

Hospital staff like the Disinfector too.

“It is pretty simple to use and seems to be working great,” said Stephanie Fowler of Environmental Services, who activates the robot after a room is cleaned with traditional methods.

The R-D Rapid Disinfector was developed by a Rochester firm, Steriliz LLC, and is manufactured locally. The Disinfector uniquely provides FDA-patented wireless sensors to measure the amount of UV-C light delivered to an area and real-time online data access and reports. Since being tried in four Rochester hospitals in 2011, several hundred of these Disinfectors are now being used in hospitals, care homes, disaster centers and government installations worldwide.

Steriliz is recognized as a world leader in UV-C disinfection.

“Improving the health and safety of patients is a blessed opportunity,” said CEO and President Sam Trapani. “The potential market for the company’s product is large and we are experiencing a high growth curve.”

To read the article in its entirety please click on the link below:

http://www.mpnnow.com/news/20170318/robot-destroys-germs-with-power-of-light